Floatz logo

nc762

Advanced or Metastatic Solid Tumors

NextCure, Inc.Phase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Cyclophosphamide
Beijing Biotech
Phase 1/2B
Epirubicin
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Eloxatin
ASLAN Pharmaceuticals
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Merck Sharp & Dohme LLC
Phase 1/2CCC

View all 50 →

Same molecule, other indications

nc762 is also rated in:

ovarian cancerDormant
CC
Indicative ·
40 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
breast cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →